ESMO Breast 2022 | eRAPID improves patient self-management of cancer treatment side-effects

Galina Velikova, MD, PhD, St. James’s University Hospital Leeds, Leeds, UK, provides an overview of eRAPID, the electronic self-reporting of adverse events for patients during and after cancer treatment. A randomized clinical trial involving eRAPID demonstrated a benefit to patients in managing their symptoms without increasing hospital workload. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.